Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.
Journal
Obesity (Silver Spring, Md.)
ISSN: 1930-739X
Titre abrégé: Obesity (Silver Spring)
Pays: United States
ID NLM: 101264860
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
16
12
2022
received:
21
10
2022
accepted:
12
01
2023
pubmed:
7
3
2023
medline:
23
3
2023
entrez:
6
3
2023
Statut:
ppublish
Résumé
This study assessed the effects of semaglutide on body weight, cardiometabolic risk factors, and glycemic status in individuals categorized by baseline BMI with or without additional obesity-related comorbidities, including prediabetes and high risk of cardiovascular disease (CVD). This was a post hoc exploratory subgroup analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) 1 trial (NCT03548935), in which participants without diabetes and BMI ≥30 kg/m Mean changes in body weight from baseline to week 68 with semaglutide were -16.2% and -14.0% in the subgroups with baseline BMI <35 and ≥35 kg/m This subgroup analysis confirms that semaglutide is effective in individuals with baseline BMI <35 and ≥35 kg/m
Substances chimiques
semaglutide
53AXN4NNHX
Glucagon-Like Peptides
62340-29-8
Banques de données
ClinicalTrials.gov
['NCT03548935']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
990-999Informations de copyright
© 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
Références
Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
Davies M, Faerch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
Wadden TA, Bailey TS, Billings LK, et al; STEP 3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413.
Rubino D, Abrahamsson N, Davies M, et al; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11-22.
Kushner RF, Garvey WT, Hesse D, et al. Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1) [abstract]. J Endocr Soc. 2021;5(suppl 1):A24.
Kushner RF, Garvey WT, Hesse D, et al. Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1) [poster]. Accessed November 1, 2022. https://sciencehub.novonordisk.com/content/hcpexperience/kol/en/congresses/endo2021/endo21-step-1-resp-analys.html.
Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20(9):2210-2219.
Leiter L, Charpentier G, Chaykin L, et al. Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1-5 [abstract]. Can J Diabetes. 2017;41(5):S6.
Aroda VR, Bauer R, Christiansen E, et al. Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obes Metab. 2022;24(7):1338-1350.
Yale JF, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022;10(2):e002619. doi:10.1136/bmjdrc-2021-002619
Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.
Husain M, Birkenfeld AL, Donsmark M, et al; PIONEER 6 Investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841-851.
Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442-451.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes: prevention in people at high risk. Published July 12, 2012. Updated September 15, 2017. Accessed November 1, 2022. https://www.nice.org.uk/guidance/ph38.
National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. Published July 18, 2014. Updated February 10, 2023. Accessed November 1, 2022. https://www.nice.org.uk/guidance/cg181.
National Institute for Health and Care Excellence (NICE). Liraglutide for managing overweight and obesity. Published December 9, 2020. Accessed December 1, 2022. https://www.nice.org.uk/guidance/ta664/chapter/3-Committee-discussion.
Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46.
Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002;2:8. doi:10.1186/1471-2288-2-8
Althouse AD. Adjust for multiple comparisons? It's not that simple. Ann Thorac Surg. 2016;101(5):1644-1645.
Perreault L, Davies M, Frias JP, et al. Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program. Diabetes Care. 2022;45(10):2396-2405.
Okunogbe A, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022;7(9):e009773. doi:10.1136/bmjgh-2022-009773
World Obesity Federation. Global data on cost of consequences of obesity. Accessed November 1, 2022. https://www.worldobesity.org/resources/resource-library/calculating-the-costs-of-the-consequences-of-obesity.
Hu Y, Zheng SL, Ye XL, et al. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Ann Transl Med. 2022;10(3):152. doi:10.21037/atm-22-200
Lee M, Lauren BN, Zhan T, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract. 2020;6(2):162-170.
Kim N, Wang J, Burudpakdee C, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022;28(7):740-752.
Olivieri AV, Larsen S, Luckevich M, Chan K, Lamotte M. The cost-effectiveness of subcutaneous semaglutide 2.4 mg injection in the management of obesity in Canada using the core obesity model [abstract EE464]. Value Health. 2022;25(7 suppl):S426. doi:10.1016/j.jval.2022.04.712
Hunt B, Malkin SJP, Moes RGJ, Huisman EL, Vandebrouck T, Wolffenbuttel BHR. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in The Netherlands. BMJ Open Diabetes Res Care. 2019;7(1):e000705. doi:10.1136/bmjdrc-2019-000705
Capehorn M, Hallén N, Baker-Knight J, Glah D, Hunt B. Evaluating the cost-effectiveness of once-weekly semaglutide 1 mg versus empagliflozin 25 mg for treatment of patients with type 2 diabetes in the UK setting. Diabetes Ther. 2021;12(2):537-555.
Malkin SJP, Carvalho D, Costa C, Conde V, Hunt B. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetol Metab Syndr. 2022;14(1):32. doi:10.1186/s13098-022-00801-4
Risebrough NA, Baker TM, Zhang L, Ali SN, Radin M, Dang-Tan T. Lifetime cost-effectiveness of oral semaglutide versus dulaglutide and liraglutide in patients with type 2 diabetes inadequately controlled with oral antidiabetics. Clin Ther. 2021;43(11):1812-1826.e1817.
Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes. J Manag Care Spec Pharm. 2021;27(4):455-468.
Cui J, Klepser DG, McAdam-Marx C. Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States. J Manag Care Spec Pharm. 2021;27(7):840-845.
Evans M, Chubb B, Malkin SJP, Berry S, Lawson J, Hunt B. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: a long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes Obes Metab. 2022;25(2):491-500.
Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today. 2015;50(3):117-128.
Kuk JL, Rotondi M, Sui X, Blair SN, Ardern CI. Individuals with obesity but no other metabolic risk factors are not at significantly elevated all-cause mortality risk in men and women. Clin Obes. 2018;8(5):305-312.
Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69.
Verma S, Bhatta M, Davies M, et al. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials. EClinicalMedicine. 2023;55:101737. doi:10.1016/j.eclinm.2022.101737
Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785.
Lee MMY, Kristensen SL, Gerstein HC, McMurray JJV, Sattar N. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr. 2022;16(1):102382. doi:10.1016/j.dsx.2021.102382
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.
Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468-478.